2026-04-17T10:14:40Zhttps://recercat.cat/oai/request

oai:recercat.cat:10256/165022024-06-18T12:40:30Zcom_2072_452955com_2072_2054col_2072_453079

2024-06-18T12:40:30Z urn:hdl:10256/16502 Correlation between mutational status and survival and second cancer risk assessment in patients with gastrointestinal stromal tumors: a population-based study Rubió Casadevall, Jordi Lluis Borràs, Joan Carmona García, Maria Carme Ameijide, Alberto González Vidal, Allan Ortiz Duran, Maria Rosa Bosch, Ramon Riu, Francesc Parada, David Martí, Esther Miró, Josefina Sirvent, Juan José Galceran, Jaume Marcos-Gragera, Rafael Sarcoma Tumors del estroma gastrointestinal Gastrointestinal stromal tumors Gastrointestinal stromal tumors are sarcomas of the digestive tract characterized by mutations mainly located in the c-KIT or in the platelet-derived growth factor receptor (PDGFR)-alpha genes. Mutations in the BRAF gene have also been described. Our purpose is to define the distribution of c-KIT, PDGFR and BRAF mutations in a population-based cohort of gastrointestinal stromal tumors (GIST) patients and correlate them with anatomical site, risk classification and survival. In addition, as most of the GIST patients have a long survival, second cancers are frequently diagnosed in them. We performed a second primary cancer risk assessment. Methods: Our analysis was based on data from Tarragona and Girona Cancer Registries. We identified all GIST diagnosed from 1996 to 2006 and performed a mutational analysis of those in which paraffin-embedded tissue was obtained. Observed (OS) and relative survival (RS) were calculated according to risk classifications and mutational status. Multivariate analysis of variables for observed survival and was also done. Results: A total of 132 GIST cases were found and we analyzed mutations in 108 cases. We obtained 53.7% of mutations in exon 11 and 7.4% in exon 9 of c-KIT gene; 12% in exon 18 and 1.9% in exon 12 of PDGFR gene and 25% of cases were wild type GIST. Patients with mutations in exon 11 of the c-KIT gene had a 5-year OS and RS of 59.6% and 66.3%, respectively. Patients with mutations in exon 18 of the PDGFR gene had a 5-year OS and RS of 84.6% and 89.7%. In multivariate analysis, only age and risk group achieved statistical significance for observed survival. GIST patients had an increased risk of second cancer with a hazard ratio of 2.47. Conclusions: This population-based study shows a spectrum of mutations in the c-KIT and PDGFR genes in GIST patients similar to that previously published. The OS and RS of GIST with the exon 18 PDGFR gene mutation could indicate that this subgroup of patients may be less aggressive and have a good prognosis, although less sensitive to treatment at recurrence. In our study, GIST patients have an increased risk of developing a second neoplasm 2024-06-18T12:40:30Z 2024-06-18T12:40:30Z 2015-02-13 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion peer-reviewed http://hdl.handle.net/10256/16502 info:eu-repo/semantics/altIdentifier/doi/10.1186/s12957-015-0474-0 info:eu-repo/semantics/altIdentifier/issn/1477-7819 info:eu-repo/semantics/altIdentifier/eissn/1477-7819 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess BioMed Central World Journal of Surgical Oncology, 2015, vol. 13, p. 47 Articles publicats (IdIBGi)